share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外国发行人报告
美股sec公告 ·  06/27 08:03
Moomoo AI 已提取核心信息
NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of June 2024. On June 26, 2024, the company amended two warrants with a certain institutional investor. The first amendment pertains to a 2023 Warrant initially issued in June 2023, which has been modified to adjust the 'Redemption Right' and extend its termination date to October 12, 2029. The second amendment extends the termination date of a 2024 Warrant, issued in April 2024, also to October 12, 2029. These amendments are detailed in Exhibits 10.1 and 10.2 attached to the Form 6-K report. The report also states that it will be incorporated by reference into the company's existing Registration Statements on Form S-8 and Form F-3.
NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of June 2024. On June 26, 2024, the company amended two warrants with a certain institutional investor. The first amendment pertains to a 2023 Warrant initially issued in June 2023, which has been modified to adjust the 'Redemption Right' and extend its termination date to October 12, 2029. The second amendment extends the termination date of a 2024 Warrant, issued in April 2024, also to October 12, 2029. These amendments are detailed in Exhibits 10.1 and 10.2 attached to the Form 6-K report. The report also states that it will be incorporated by reference into the company's existing Registration Statements on Form S-8 and Form F-3.
NeuroSense Therapeutics Ltd.,一家外国私募发行人,已向美国证券交易所(SEC)提交了2024年6月的报告。2024年6月26日,该公司与某机构投资者修改了两项认股权证。第一项修改涉及2023年在6月份首次发行的认股权证,已经调整了“赎回权”,并将其终止日期延长至2029年10月12日。第二项修改将在2024年4月发行的认股权证的终止日期也延长至2029年10月12日。这些修改在提交的6-K表格中的展示10.1和10.2中详细说明。报告还指出,它将作为参考附在公司现有的S-8和F-3表格的注册声明中。
NeuroSense Therapeutics Ltd.,一家外国私募发行人,已向美国证券交易所(SEC)提交了2024年6月的报告。2024年6月26日,该公司与某机构投资者修改了两项认股权证。第一项修改涉及2023年在6月份首次发行的认股权证,已经调整了“赎回权”,并将其终止日期延长至2029年10月12日。第二项修改将在2024年4月发行的认股权证的终止日期也延长至2029年10月12日。这些修改在提交的6-K表格中的展示10.1和10.2中详细说明。报告还指出,它将作为参考附在公司现有的S-8和F-3表格的注册声明中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息